新喹诺酮类药物研究进展(3)
6郭惠元,顾慧儿.吡酮酸化学进展[J].国外医药抗生素分册，2001,22(1):5-14
7Chu DTW,Fernandes PB.Structure-activity relationships of thefluoquinolones[J].Antimicrob Agents Chemother,1989,33:131 8Pendland SL,Neuhauser MM,Garey KW.Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical iso lates:impact ofbacterial strain and antibiotic concentration[J]. Diagn Microbiol Infect Dis.2002 Sep,44(1):59-61
9Hurst M,Lamb HM,Scott LJ,Figitt DP.Levofloxacin:an up dated review of its use in the treatment of bacterial infections[J].Drugs,2002,62(14):2127-2167
, http://www.100md.com
10Schentag JJ.Pharmacokinetics and pharmacodynamic predictorsof antimicrobial efficacy:moxifloxacin and Stretococcus penu monae[J].J Chemother,2002 Feb,14 Suppl 2:13-21
11张京.新喹诺酮类药物在社区获得性呼吸道感染中的应用价值.中华结核和呼吸杂志,2001，12(4):45-48
12Gotfried M,Quinn TC,Gothelf S.Oral gatifloxacin in outpatient community——acquired pneumonia:results from TeqCES,A community-based,open-label,multicenter study[J].Diang Microbiol Infect Dis,2002 Sep,44(1):85-91
, 百拇医药
13陶然，周越塑，王二平，等.司帕沙星与氧氟沙星治疗沙眼衣原体性尿道炎(宫颈炎)临床疗效对比研究[J]. 中国抗生素杂志,1999,24(3):239
14Hu Y,Coates AR,Mtchison DA.Sterilizing Activities of Fluoroquinolones against Rifampin-tolerant of Mycobacterium tuberculosis[J].Antimicrob Agents Chemother.2003 Feb;47(2): 653-657 Tarshis GA,M Skin BM,Jones TM.Once-daily oral gatifloxacinversus oral levofloxacin in treatment of uncomplicated skin and tissue infections: double-blind,multi center,randomized study[J].Antimicrob Agents Chemother,2001 Aug,45(8)： 2358-2362
, http://www.100md.com
15Fish DN,North DS.Gatifloxacin,an advanced 8-methoxy fluoroquinolone[J].Pharmacocotherapy,2001 Jan,21(1):35-59
16Drago L,De Vecchi E,Lombardi A,et al.Bactericidal activity of levofloxacin,gatifloxacin,penicillin,meopenem,and rokitamycin against Bacillus anthracis clinical isolates.J Autimicrob chemother. Antimicrob Chemother,2002 Dec,50(6):1059-1063
17Trampuz a,Laifer G,Wenk M.Pharmacokinetics andpharma- codynamicsof gatifloxacin against Streptococcus pneumoiae and Staphylococcus aureus in a granulocyte-rich exudate[J]. Antimicrob Agents Chemother,2002 Nov,46(11):3630-3633
, 百拇医药
18Franca SA,Carvalho CR.Effectiveness,safety and tolerability ofgatifloxacin,a new 8-methoxyfluoroquinolone,in the treatment of outpatients with community-acquiredpneuminia:a Brazilian study[J].Braz J Infect Dis,2002 Aug,6(4):157-163
19Nicodemo AC,Mendes CM,O plustil CP.In vitro activity of floroquinolones(gatifloxacin,levofloxacin and trovafloxacin)and seven other antibiotics against Streptococcus pneumoniae[J]. Braz J Infect Dis,2002 Apr,5(2):50-52
, 百拇医药
20Rubinstein E.History of quinolones and their side effects[J].Chemotherapy,2001,47 Suppl 3:3-8
21Theomioka H,Sato K.Comparative antibacterial activities of the newly synthesizel quinolone AM-1155,sparfloxacin,and ofloxaicn[J].Antimicrob Agents Chemother,1993,37(6):1259
22Li Q,et al.Adverse drug reaction of quinolones from standpoints of pharmacokinetics[J].Antimicrob Agents Chemother,2002,46(5):1262
, http://www.100md.com
23Tsurumaki Y，Manda H，Takei M.In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from resprication tract,urinary tract and surgical infections during 1997-1998 in Japan[J].J Antimicrob Chemother,2000,45(5):685-689
24Blondeau JM,Zhao X,Hansen G,et al.Mautant prevention concentrations of fluoroquinolones for clinical isolates of Stretococcus pneumoniae.Antimicrob Agents Chemother,2001 Feb,45(2):433-438
25Artymowicz RJ,Cino BJ,Rossi JG,et al.Possible interraction between gatifloxacin and warfarin[J].Am J Health Syst Pharm,2002,Jun 15,59(12):1205-1206
26刘明亮，郭惠元，等.喹诺酮类抗菌药的概况与展望及研究新进展[J].国外医药抗生素分册，2001，22(1)：1-4
(收稿日期：2007-05-19), http://www.100md.com(李宏力)
7Chu DTW,Fernandes PB.Structure-activity relationships of thefluoquinolones[J].Antimicrob Agents Chemother,1989,33:131 8Pendland SL,Neuhauser MM,Garey KW.Comparative killing rates of gatifloxacin and ciprofloxacin against 14 clinical iso lates:impact ofbacterial strain and antibiotic concentration[J]. Diagn Microbiol Infect Dis.2002 Sep,44(1):59-61
9Hurst M,Lamb HM,Scott LJ,Figitt DP.Levofloxacin:an up dated review of its use in the treatment of bacterial infections[J].Drugs,2002,62(14):2127-2167
, http://www.100md.com
10Schentag JJ.Pharmacokinetics and pharmacodynamic predictorsof antimicrobial efficacy:moxifloxacin and Stretococcus penu monae[J].J Chemother,2002 Feb,14 Suppl 2:13-21
11张京.新喹诺酮类药物在社区获得性呼吸道感染中的应用价值.中华结核和呼吸杂志,2001，12(4):45-48
12Gotfried M,Quinn TC,Gothelf S.Oral gatifloxacin in outpatient community——acquired pneumonia:results from TeqCES,A community-based,open-label,multicenter study[J].Diang Microbiol Infect Dis,2002 Sep,44(1):85-91
, 百拇医药
13陶然，周越塑，王二平，等.司帕沙星与氧氟沙星治疗沙眼衣原体性尿道炎(宫颈炎)临床疗效对比研究[J]. 中国抗生素杂志,1999,24(3):239
14Hu Y,Coates AR,Mtchison DA.Sterilizing Activities of Fluoroquinolones against Rifampin-tolerant of Mycobacterium tuberculosis[J].Antimicrob Agents Chemother.2003 Feb;47(2): 653-657 Tarshis GA,M Skin BM,Jones TM.Once-daily oral gatifloxacinversus oral levofloxacin in treatment of uncomplicated skin and tissue infections: double-blind,multi center,randomized study[J].Antimicrob Agents Chemother,2001 Aug,45(8)： 2358-2362
, http://www.100md.com
15Fish DN,North DS.Gatifloxacin,an advanced 8-methoxy fluoroquinolone[J].Pharmacocotherapy,2001 Jan,21(1):35-59
16Drago L,De Vecchi E,Lombardi A,et al.Bactericidal activity of levofloxacin,gatifloxacin,penicillin,meopenem,and rokitamycin against Bacillus anthracis clinical isolates.J Autimicrob chemother. Antimicrob Chemother,2002 Dec,50(6):1059-1063
17Trampuz a,Laifer G,Wenk M.Pharmacokinetics andpharma- codynamicsof gatifloxacin against Streptococcus pneumoiae and Staphylococcus aureus in a granulocyte-rich exudate[J]. Antimicrob Agents Chemother,2002 Nov,46(11):3630-3633
, 百拇医药
18Franca SA,Carvalho CR.Effectiveness,safety and tolerability ofgatifloxacin,a new 8-methoxyfluoroquinolone,in the treatment of outpatients with community-acquiredpneuminia:a Brazilian study[J].Braz J Infect Dis,2002 Aug,6(4):157-163
19Nicodemo AC,Mendes CM,O plustil CP.In vitro activity of floroquinolones(gatifloxacin,levofloxacin and trovafloxacin)and seven other antibiotics against Streptococcus pneumoniae[J]. Braz J Infect Dis,2002 Apr,5(2):50-52
, 百拇医药
20Rubinstein E.History of quinolones and their side effects[J].Chemotherapy,2001,47 Suppl 3:3-8
21Theomioka H,Sato K.Comparative antibacterial activities of the newly synthesizel quinolone AM-1155,sparfloxacin,and ofloxaicn[J].Antimicrob Agents Chemother,1993,37(6):1259
22Li Q,et al.Adverse drug reaction of quinolones from standpoints of pharmacokinetics[J].Antimicrob Agents Chemother,2002,46(5):1262
, http://www.100md.com
23Tsurumaki Y，Manda H，Takei M.In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from resprication tract,urinary tract and surgical infections during 1997-1998 in Japan[J].J Antimicrob Chemother,2000,45(5):685-689
24Blondeau JM,Zhao X,Hansen G,et al.Mautant prevention concentrations of fluoroquinolones for clinical isolates of Stretococcus pneumoniae.Antimicrob Agents Chemother,2001 Feb,45(2):433-438
25Artymowicz RJ,Cino BJ,Rossi JG,et al.Possible interraction between gatifloxacin and warfarin[J].Am J Health Syst Pharm,2002,Jun 15,59(12):1205-1206
26刘明亮，郭惠元，等.喹诺酮类抗菌药的概况与展望及研究新进展[J].国外医药抗生素分册，2001，22(1)：1-4
(收稿日期：2007-05-19), http://www.100md.com(李宏力)